Skip to main content
. 2020 Aug 3;12(8):2146. doi: 10.3390/cancers12082146

Figure 2.

Figure 2

The overall survival (OS), progression-free survival (PFS) and post-progression survival (PPS) according to the modified albumin-bilirubin (mALBI). The median survival time (MST) was not reached in the mALBI 1/2a group and 12.5 months in the mALBI 2b group (p < 0.01) (A). The median PFS was 6.2 months in the mALBI 1/2a group and 4.4 months in the mALBI 2b group (p = 0.48) (B). The median PPS was 12.6 months in the mALBI 1/2a group and 2.9 months in the mALBI 2b group (p < 0.01) (C).